BioSpace News Archive

ChromaDex Corp., the global authority on nicotinamide adenine dinucleotide research with a focus on healthy aging, announced its inclusion in the Russell 2000® Index as part of the annual reconstitution of the Russell stock indexes.

TRACON Pharmaceuticals (NASDAQ: TCON) today announced the objective response rate (ORR) by blinded independent central review (BICR) in the fully enrolled ENVASARC pivotal trial in the 82 evaluable patients is 5% (four responders), which is lower than the primary endpoint of the study of 11% ORR by BICR needed to support a biologics license application (BLA).

Sera Prognostics Inc. announced that as a result of the annual Russell Reconstitution being finalized on June 28, 2024, the Company has been added to the Russell Small-Cap 2000 and Russell 3000 indexes effective with the opening of equity markets today.